Captrust Financial Advisors Invests $118,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

Captrust Financial Advisors purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,820 shares of the company’s stock, valued at approximately $118,000.

A number of other large investors have also modified their holdings of the business. Millennium Management LLC grew its stake in shares of Vir Biotechnology by 94.6% during the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after acquiring an additional 606,804 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Vir Biotechnology by 13.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after acquiring an additional 136,087 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Vir Biotechnology by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after acquiring an additional 6,359 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Vir Biotechnology by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after acquiring an additional 58,360 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Vir Biotechnology by 19,327.1% during the second quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock worth $2,671,000 after acquiring an additional 298,603 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Price Performance

Shares of VIR stock opened at $7.56 on Tuesday. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -1.93 and a beta of 0.49. The stock has a 50 day simple moving average of $8.03 and a 200-day simple moving average of $8.61. Vir Biotechnology, Inc. has a 1-year low of $6.56 and a 1-year high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. During the same period in the prior year, the company posted ($1.22) earnings per share. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year. Analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Barclays dropped their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).